Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study

S. Gerdes*, D. Tha├ži, C. E.M. Griffiths, P. Arenberger, J. Poetzl, G. Wuerth, M. Afonso, H. Woehling

*Corresponding author for this work
37 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study'. Together they form a unique fingerprint.

Medicine & Life Sciences